PD-1 AXIS BINDING ANTAGONIST TO TREAT CANCER WITH GENETIC MUTATIONS IN SPECIFIC GENES
The present disclosure describes combination therapies comprising a PD-1 axis binding antagonist, wherein the cancer has been pre-determined to have one or more genetic mutations in one or more genes, to have certain gene expression profiles, and/or to have other biomarkers. La présente invention co...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
10.12.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present disclosure describes combination therapies comprising a PD-1 axis binding antagonist, wherein the cancer has been pre-determined to have one or more genetic mutations in one or more genes, to have certain gene expression profiles, and/or to have other biomarkers.
La présente invention concerne des polythérapies comprenant un antagoniste de liaison à l'axe PD-1, le cancer ayant été prédéterminé comme ayant une ou plusieurs mutations génétiques dans un ou plusieurs gènes, comme ayant certains profils d'expression génique et/ou comme ayant d'autres biomarqueurs. |
---|---|
Bibliography: | Application Number: WO2020EP65038 |